Not all Alzheimer’s research has been compromised by allegations of scientific fraud. But we should interrogate whether the governing bodies of research and drug approvals are truly effective.
Machine learning is great at finding patterns but doesn’t know what those patterns mean. Combine it with knowledge gained from genetic research and you have a powerful view into the workings of cells.
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
Clinical trials of the drug have shown mixed results.
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
The first drug targeting Alzheimer’s disease has been approved in 20 years – but its approval isn’t based on substantial evidence.
The researchers developed a molecule which works to stop toxic proteins from building up in the brain.
Having extra copies of a gene called BACE2 can slow down the development of Alzheimer’s disease in human brain cells.
In mice, we found that drugs developed to treat Alzheimer’s Disease could be re-purposed to prevent, or even reverse, the blood vessel damage caused by obesity and type 2 diabetes.
Blacks are at higher risk for many diseases. This is partly due to poverty, discrimination and lack of access to care. But there may be something different about the higher rates of Alzheimer’s.